Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
213 hedge funds and large institutions have $3.53B invested in Mirati Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 94 increasing their positions, 50 reducing their positions, and 38 closing their positions.
224% more call options, than puts
Call options by funds: $75.7M | Put options by funds: $23.3M
88% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 50
48% more capital invested
Capital invested by funds: $2.38B → $3.53B (+$1.15B)
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
21% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 38
3% more funds holding
Funds holding: 207 → 213 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$205M |
| 2 |
RI
RTW Investments
New York
|
+$82M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$50.1M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$42.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$93.3M |
| 2 |
PA
Perceptive Advisors
New York
|
-$26M |
| 3 |
Millennium Management
New York
|
-$16.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$15.6M |
| 5 |
Morgan Stanley
New York
|
-$13.7M |
MRTX Hedge Fund Activity: Q3 2023 in Review
213 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2023, worth a combined $3.53B — up 48% from $2.38B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new MRTX positions and 38 closed out — a net gain of 8 holders — while 94 added to existing stakes and 50 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $205M. The largest seller was Armistice Capital, cutting an estimated $93.3M.
- 213 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2023, up from 207 in Q2 2023.
- Funds reported $3.53B of Mirati Therapeutics, Inc. Common Stock stock for Q3 2023, up 48% quarter-over-quarter.
- 46 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2023 and 38 closed out, a net change of +8 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2023 was EcoR1 Capital, an estimated $205M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2023 was Armistice Capital, an estimated $93.3M sold.
Based on aggregated 13F filings for Q3 2023.